Search results
The Zacks Analyst Blog Highlights Stocks recently featured in the blog include: The Goldman Sachs,...
Zacks via Yahoo Finance· 3 hours agoThe Zacks Consensus Estimate for current-year earnings has improved 0.9% over the last 30 days....
Imvax concludes enrolment in Phase IIb glioblastoma treatment trial
Clinical Trials Arena via Yahoo Finance· 3 hours agoProgression-free survival (PFS) is the trial’s primary endpoint while overall survival (OS) and...
Ogden elementary school earns International Baccalaureate ‘World School’ designation
Standard-Examiner· 1 day agoIn a press release, the Ogden School District announced that Liberty Elementary School is now a...
SSIS becomes candidate for IB program | Your Observer
The Longboat Observer· 6 days agoRooted in the Theory of Multiple Intelligences developed in the 1980s by psychologist Howard...
Moleculin begins NIH-funded Phase II glioblastoma treatment trial
Clinical Trials Arena via Yahoo Finance· 6 days agoThe primary goal of the study is to measure progression-free survival, while secondary outcomes...
Kodiak (KOD) Q1 Loss Narrower Than Expected, Pipeline in Focus
Zacks via Yahoo Finance· 6 days agoDuring the same time frame, the consensus estimate for 2025 earnings per share has remained constant...
Genentech Reports Positive Phase Ib Results for Its Dual GLP-1/GIP Receptor Agonist CT-388 in People...
Benzinga· 6 days ago– Over 24 weeks, a once-weekly subcutaneous injection of CT-388 achieved a clinically meaningful and statistically significant mean placebo-adjusted weight loss of 18.8% (p < 0.001) – – At week 24, 100% of CT-388
Q1 2024 Panbela Therapeutics Inc Earnings Call
Thomson Reuters StreetEvents via Yahoo Finance· 6 days agoIn the second half of this year, we anticipate opening the neoadjuvant pancreatic cancer trial, opening the Phase II ovarian trial, publishing the final Phase I/Ib ...
Positive Clinical Results from HyBryte™ Compatibility Study in the Treatment of Cutaneous T-Cell...
WFRV 5 Green Bay· 6 days agoSoligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an ...
